細胞形態(tài)：淋巴樣
免疫類型：IgG1
是否是腫瘤細胞：0
物種來源：小鼠
生長狀態(tài)：懸浮生長
數(shù)量：大量
ATCC Number：HB-8110?
運輸方式：凍存運輸
規(guī)格：0.1ml Designations: B38.1
Depositors: ?NIH
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human mammary tumor cells
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with membrane enriched fractions of extracts from either of two human breast tumor metastases to the liver (Met 1 and Met 2).
Spleen cells were fused with NS-1 myeloma cells.
The antibody reacts weakly with extracts of both metastases and with live cells, and strongly with live BT-20 (ATCC HTB-19 ), MCF7 (ATCC HTB-22 ) and or ZR-75-1 (ATCC CRL-1500 ) mammary carcinoma cells.
The antibody does not react with liver extracts or a variety of live normal and sarcoma cells.
Propagation: ATCC complete growth medium: Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:5 is recommended
Medium Renewal: 3 times per week
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium, 92.5%; DMSO, 7.5%
References: 1177: Colcher D, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA 78: 3199-3203, 1981. PubMed: 6789331
3537: Colcher D, et al. Process for producing monoclonal antibodies reactive with human breast cancer. US Patent 4,522,918 dated Jun 11 1985
